SLC25A32 and neoplasm: We show that SLC25A32 is highly amplified in different tumor types and that gene amplification correlates with increased mRNA expression and reduced patients ́ survival, emphasizing its prominent clinical relevance and high potential as a novel target for cancer therapy.